745P - Ovarian Cancer Retrospective European (O’CaRE) observational study to assess burden of disease and time to next treatment in real-world clinical practice: Results from the United Kingdom (UK)

Background

The retrospective O’CaRE study assessed real-world burden of disease, treatment patterns, and outcomes in patients (pts) with ovarian cancer (OC) through analysis of healthcare data across 5 European countries. Interim results are reported herein for the UK cohort.

Methods

O’CaRE was a multicenter, retrospective, noninterventional study conducted using medical records from pts aged ≥18 y diagnosed with epithelial ovarian, fallopian tube, or primary peritoneal cancer from Jan 1, 2014, to Dec 31, 2015. Pts who received PARP inhibitor (PARPi) treatment as investigational medicine were ineligible. Pts were followed from index date (ID), defined as the date of diagnosis, until last activity or end of the observation period. Kaplan-Meier methodology was used to estimate time to next treatment 1 (TTNT1, time from last recorded first-line [1L] dose to start of 2L treatment), TTNT2 (time from end of 2L to start of 3L treatment), and TTNT3 (time from end of 3L to start of 4L treatment).

Results

The UK cohort included 166 pts. At ID, median age was 65 y; 50.6% and 15.7% of pts had FIGO stage III or IV cancer, respectively. For 1L treatment, 50.0% of pts received surgery + chemo (primary debulking surgery [PDS], 30.7%; interval debulking surgery [IDS], 19.3%), 25.9% chemo alone, and 15.1% surgery + chemo + antiangiogenic therapy (PDS, 6.0%; IDS, 8.4%; PDS + secondary debulking surgery, 0.6%). During follow-up, 99.4%, 59.6%, 28.3%, 11.4% of pts received ≥1, 2, 3, or 4 lines of therapy, respectively. Only 3.0% of pts received PARPi maintenance therapy. Outcomes generally worsened and median TTNT decreased with each progressive line of therapy (TTNT1, 2, and 3 were 15.7, 6.7, and 5.9 mo, respectively; Table). Table: 745P

^a1 pt had 3L treatment ongoing and was therefore not included in TTNT3 analysis.

Conclusions

Despite advances in treatment, there is still an unmet need in pts with OC as there is significant mortality and most pts require multiple lines of therapy.

Clinical trial identification

NA

Editorial acknowledgement

Writing and editorial support, funded by GlaxoSmithKline (Waltham, MA, USA) and coordinated by Johanna Bruneau, PhD, of GlaxoSmithKline, were provided by Betsy Taylor, PhD, and Jennifer Robertson, PhD, of Ashfield MedComms, an Ashfield Health company (Middletown, CT, USA).

Legal entity responsible for the study

GlaxoSmithKline.

Funding

GlaxoSmithKline.

Disclosure

J. McGrane: Financial Interests, Institutional, Advisory Board: GlaxoSmithKline, Ipsen, Roche, BMS, Merck, Ferring; Financial Interests, Institutional, Invited Speaker, speaking events at educational meetings: GlaxoSmithKline, Ipsen, Pfizer, Astellas, Roche, BMS, and Bayer; Financial Interests, Personal, Other, travel grants: Astellas, GlaxoSmithKline and BMS. D. Shaw: Financial Interests, Personal, Other, Funding for travel: GlaxoSmithKline. A. Anand: Financial Interests, Personal, Advisory Board: GlaxoSmithKline; Financial Interests, Personal, Invited Speaker, speaking at educational events: GlaxoSmithKline, AstraZeneca and Clovis Oncology. J. Krell: Financial Interests, Institutional, Advisory Role: GlaxoSmithKline. L. Saunders: Financial Interests, Institutional, Sponsor/Funding, Open Health, which is being funded for their work in this project by GlaxoSmithKline: GlaxoSmithKline, Open Health. C. Hawkes: Financial Interests, Personal, Full or part-time Employment: GlaxoSmithKline. J.M. Schilder: Financial Interests, Personal, Full or part-time Employment: GlaxoSmithKline. W. York: Financial Interests, Personal, Full or part-time Employment: GlaxoSmithKline. J. Astrom: Financial Interests, Personal, Full or part-time Employment: GlaxoSmithKline. All other authors have declared no conflicts of interest.